{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:47:07Z","timestamp":1747223227460,"version":"3.40.5"},"reference-count":0,"publisher":"Pensoft Publishers","issue":"5","license":[{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FM"],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> The T315I mutation in patients with chronic myeloid leukemia (CML) has been associated with therapeutic resistance and an unfavourable prognosis.<\/jats:p>\n          <jats:p><jats:bold>Aim:<\/jats:bold> To study the frequency of T315I mutation in patients with CML, BCR-ABL&amp;nbsp;(+), their clinical characteristics, disease evolution, and median survival.<\/jats:p>\n          <jats:p><jats:bold>Patients and methods:<\/jats:bold> We studied 75 patients with CML and BCR-ABL1&amp;nbsp;(+). T315I mutation was detected by digital droplet PCR and BCR-ABL1 was analyzed by RT-PCR. A comparative analysis was performed by sex, age, disease phase, risk group, treatment, molecular response (MR), and median survival in T315I&amp;nbsp;(+) and T315I&amp;nbsp;(&amp;minus;) patients.<\/jats:p>\n          <jats:p><jats:bold>Results:<\/jats:bold> T315I mutation was detected in 11 patients (14.7%). No significant difference was found in the phase, risk group, and first-line therapy. A significantly higher proportion of T315I&amp;nbsp;(+) did not achieve MR&amp;nbsp;&gt;3.5 log: 8 (72.7%) vs. 22 (34.4%) (<jats:italic>p<\/jats:italic>=0.023). The lowest mean BCR-ABL1 levels were significantly higher in the CML T315I&amp;nbsp;(+) group compared to the CML T315I&amp;nbsp;(&amp;minus;) group: 12.1&amp;plusmn;6.0 vs. 3.77&amp;plusmn;1.28 (<jats:italic>p<\/jats:italic>=0.009). The median survival of T315I&amp;nbsp;(+) patients was significantly shorter: 73 months vs. 175 months (p&lt;0.0001, CI 95%).<\/jats:p>\n          <jats:p><jats:bold>Conclusions:<\/jats:bold> Our data confirm the world experience on the frequency of T315I mutation, including the unfavourable evolution, resistance to TKI treatment and short survival. ddPCR is a highly sensitive method for early detection of genetic mutations which gives the chance for effective treatment.<\/jats:p>","DOI":"10.3897\/folmed.63.e63366","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T13:35:42Z","timestamp":1635514542000},"page":"670-675","source":"Crossref","is-referenced-by-count":6,"title":["Clinical characteristics, disease evolution and survival in patients with chronic myeloid leukemia, BCR-ABL1 (+) and T315I mutation."],"prefix":"10.3897","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7811-162X","authenticated-orcid":true,"given":"Veselina","family":"Goranova-Marinova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Linev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7912-3673","authenticated-orcid":true,"given":"Hristo J.","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Zheljazkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vily","family":"Stoyanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanet","family":"Grudeva-Popova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2258","published-online":{"date-parts":[[2021,10,31]]},"container-title":["Folia Medica"],"original-title":[],"link":[{"URL":"https:\/\/foliamedica.bg\/article\/63366\/download\/pdf\/","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article\/63366\/download\/xml\/","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article_preview.php?id=63366&skip_redirect=1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T13:35:42Z","timestamp":1635514542000},"score":1,"resource":{"primary":{"URL":"https:\/\/foliamedica.bg\/article\/63366\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":0,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,10,31]]}},"URL":"https:\/\/doi.org\/10.3897\/folmed.63.e63366","relation":{},"ISSN":["1314-2143","0204-8043"],"issn-type":[{"type":"electronic","value":"1314-2143"},{"type":"print","value":"0204-8043"}],"subject":[],"published":{"date-parts":[[2021,10,31]]}}}